PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation

Overview

Journal Sci Rep

Specialty Science

Date 2018 Jun 20

PMID 29915291

Citations 13

Authors

Thomas B Davis

Mingli Yang

Michael J Schell

Heiman Wang

Le Ma

W Jack Pledger

Timothy J Yeatman

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) growth and progression is frequently driven by RAS pathway activation through upstream growth factor receptor activation or through mutational activation of KRAS or BRAF. Here we describe an additional mechanism by which the RAS pathway may be modulated in CRC. PTPRS, a receptor-type protein tyrosine phosphatase, appears to regulate RAS pathway activation through ERK. PTPRS modulates ERK phosphorylation and subsequent translocation to the nucleus. Native mutations in PTPRS, present in ~10% of CRC, may reduce its phosphatase activity while increasing ERK activation and downstream transcriptional signaling.

Citing Articles

Mass Spectrometry-Based Proteomics Analysis Unveils PTPRS Inhibits Proliferation and Inflammatory Response of Keratinocytes in Psoriasis.

Zheng X, Zhou C, Hu Y, Xu S, Hu L, Li B Inflammation. 2024; 48(1):89-103.

PMID: 38739342 DOI: 10.1007/s10753-024-02044-z.

Chronic TNF exposure induces glucocorticoid-like immunosuppression in the alveolar macrophages of aged mice that enhances their susceptibility to pneumonia.

Kruckow K, Murray E, Shayhidin E, Rosenberg A, Bowdish D, Orihuela C Aging Cell. 2024; 23(6):e14133.

PMID: 38459711 PMC: 11296116. DOI: 10.1111/acel.14133.

Identification of Novel Candidate Genes for Familial Thyroid Cancer by Whole Exome Sequencing.

Tous C, Munoz-Redondo C, Bravo-Gil N, Gavilan A, Fernandez R, Antinolo J Int J Mol Sci. 2023; 24(9).

PMID: 37175550 PMC: 10178269. DOI: 10.3390/ijms24097843.

High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma.

Lertpanprom M, Silsirivanit A, Tippayawat P, Proungvitaya T, Roytrakul S, Proungvitaya S Front Public Health. 2022; 10:835914.

PMID: 35991009 PMC: 9387352. DOI: 10.3389/fpubh.2022.835914.

Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer.

Davis T, Gupta S, Yang M, Pflieger L, Rajan M, Wang H Cancers (Basel). 2022; 14(6).

PMID: 35326598 PMC: 8945886. DOI: 10.3390/cancers14061451.

References

Gu J, Han T, Ma R, Zhu Y, Jia Y, Du J . SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer. Int J Oncol. 2013; 44(2):481-90. DOI: 10.3892/ijo.2013.2191. View

Hendriks W, Elson A, Harroch S, Pulido R, Stoker A, den Hertog J . Protein tyrosine phosphatases in health and disease. FEBS J. 2012; 280(2):708-30. DOI: 10.1111/febs.12000. View

Julien S, Dube N, Hardy S, Tremblay M . Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2010; 11(1):35-49. DOI: 10.1038/nrc2980. View

Steelman L, Chappell W, Abrams S, Kempf R, Long J, Laidler P . Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 2011; 3(3):192-222. PMC: 3091517. DOI: 10.18632/aging.100296. View

Chappell W, Steelman L, Long J, Kempf R, Abrams S, Franklin R . Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011; 2(3):135-64. PMC: 3260807. DOI: 10.18632/oncotarget.240. View

Caunt C, McArdle C . ERK phosphorylation and nuclear accumulation: insights from single-cell imaging. Biochem Soc Trans. 2012; 40(1):224-9. DOI: 10.1042/BST20110662. View

. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-7. PMC: 3401966. DOI: 10.1038/nature11252. View

Shen Y, Tenney A, Busch S, Horn K, Cuascut F, Liu K . PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science. 2009; 326(5952):592-6. PMC: 2811318. DOI: 10.1126/science.1178310. View

Suarez Pestana E, Tenev T, Gross S, Stoyanov B, Ogata M, Bohmer F . The transmembrane protein tyrosine phosphatase RPTPsigma modulates signaling of the epidermal growth factor receptor in A431 cells. Oncogene. 1999; 18(28):4069-79. DOI: 10.1038/sj.onc.1202794. View

10.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8):753-62. DOI: 10.1016/S1470-2045(10)70130-3. View

11.

Bardelli A, Siena S . Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010; 28(7):1254-61. DOI: 10.1200/JCO.2009.24.6116. View

12.

Martin K, Xu Y, Looyenga B, Davis R, Wu C, Tremblay M . Identification of PTPsigma as an autophagic phosphatase. J Cell Sci. 2011; 124(Pt 5):812-9. PMC: 3039021. DOI: 10.1242/jcs.080341. View

13.

Dry J, Pavey S, Pratilas C, Harbron C, Runswick S, Hodgson D . Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 2010; 70(6):2264-73. PMC: 3166660. DOI: 10.1158/0008-5472.CAN-09-1577. View

14.

Caunt C, Sale M, Smith P, Cook S . MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015; 15(10):577-92. DOI: 10.1038/nrc4000. View

15.

Murchie R, Guo C, Persaud A, Muise A, Rotin D . Protein tyrosine phosphatase σ targets apical junction complex proteins in the intestine and regulates epithelial permeability. Proc Natl Acad Sci U S A. 2014; 111(2):693-8. PMC: 3896190. DOI: 10.1073/pnas.1315017111. View

16.

Tonks N . Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction. FEBS J. 2012; 280(2):346-78. PMC: 3662559. DOI: 10.1111/febs.12077. View

17.

Singh H, Longo D, Chabner B . Improving Prospects for Targeting RAS. J Clin Oncol. 2015; 33(31):3650-9. DOI: 10.1200/JCO.2015.62.1052. View

18.

Sacco F, Tinti M, Palma A, Ferrari E, Nardozza A, Hooft van Huijsduijnen R . Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases. J Biol Chem. 2009; 284(33):22048-22058. PMC: 2755929. DOI: 10.1074/jbc.M109.002758. View

19.

Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G . Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol. 2012; 30(12):1288-95. DOI: 10.1200/JCO.2011.39.5814. View

20.

Wennstrom S, Downward J . Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol. 1999; 19(6):4279-88. PMC: 104388. DOI: 10.1128/MCB.19.6.4279. View